Join
Live feed
·
PRReleasevia Quantisnow
Innate Pharma S.A. ADS logo

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

ByQuantisnow·Wall Street's wire, on your screen.
IPHA· Innate Pharma S.A. ADS
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IPHA (Innate Pharma S.A. ADS) and more on Quantisnow.